Previous 10 | Next 10 |
2024-05-01 10:42:56 ET More on CytomX CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town CytomX Therapeutics, Inc. (CTMX) Q4 2023 Earnings Call Transcript CytomX upgraded to Neutral at J.P. Morgan CytomX falls as Bris...
AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024 PR Newswire Findings From Tezspire ® (tezepelumab-ekko) Phase 2a COURSE COPD Study Phase 1 Study on AMG104/AZD8630 (Inhaled Anti-TSLP) in Moderate to Severe Asthma New TAVNEOS ...
2024-04-30 11:23:00 ET More on Amgen Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock Amgen’s Blincyto data send Cullinan higher AbbVie k...
2024-04-30 03:32:48 ET More on Amgen, Sandoz Group AG, etc. Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock Amgen court hearing in patent lawsuit vs Sa...
AMGEN ANNOUNCES WEBCAST OF 2024 FIRST QUARTER FINANCIAL RESULTS PR Newswire THOUSAND OAKS, Calif. , April 29, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2024 financial results on Thursday, May 2, 2024 , afte...
2024-04-29 12:47:40 ET More on Amgen Amgen: I Prefer To Chase Value And Dividends Amgen: The Giant With An Impressive Pipeline Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock Amgen’s Blincyto data send Cullinan higher AbbVie k...
2024-04-29 08:51:30 ET Summary Immatics N.V., a European T-Cell receptor therapy company, is expected to release clinical data on all four of its candidates in 2024. The company's main focus is on developing T-cell receptor therapies for the treatment of solid tumors. Immatics...
2024-04-28 13:00:22 ET Orphan drugs -- medicines to treat rare diseases -- from Johnson & Johnson ( NYSE: JNJ ), Roche ( OTCQX:RHHBY ), and AstraZeneca ( NASDAQ: AZN ) will allow these companies to reign as the top 3 orphan drugmakers, by sales, in 2028.... Rea...
2024-04-28 08:00:00 ET As the calendar flips from April to May, the upcoming week is set to bring a flurry of earnings reports from some of the world's most prominent companies. At the top of the list, updates are anticipated from tech giants Amazon ( NASDAQ: AMZN ) and Apple ( NA...
2024-04-28 05:44:58 ET Summary Vabysmo and Phesgo are still strong growth drivers for the company going forward, growing year over year in Q1 of 2024 by 108% and 70%, respectively. Mid-single digit sales growth is expected to remain with the pipeline that it has established thus f...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 10:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-15 07:58:00 ET Can a biotechnology company pay a generous dividend in 2024? The answer is definitely yes, as Amgen (NASDAQ: AMGN) is evidently unafraid to reward its loyal shareholders with quarterly cash payments. Just as importantly, Amgen is a recent revenue growe...
2024-07-14 06:30:00 ET Income investors don't have to settle for dividends that tread water. There are plenty of stocks to buy that offer growing dividends and are poised to keep the momentum going along with attractive dividend yields . Three Motley Fool contributors think they've ...